JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

Phase 2

Recruiting

Conditions: Amyloidosis

Interventions: Drug: Daratumumab
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2022-02-22

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 150

Registration Number: NCT05250973

Locations: 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇬🇧
University College Hospital, London, United Kingdom

and more 42 locations

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Biological: JNJ-78934804
Drug: Placebo
Biological: Guselkumab
Biological: Golimumab

First Posted Date: 2022-02-16

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 703

Registration Number: NCT05242471

Locations: 🇺🇸
Moore Clinical Trials, LLC, Little Rock, Arkansas, United States
🇺🇸
Om Research LLC, Apple Valley, California, United States
🇺🇸
Valley Gastroenterology Medical Group, Arcadia, California, United States

and more 446 locations

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Phase 1

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: Cetrelimab
Drug: Placebo

First Posted Date: 2022-02-16

Last Posted Date: 2023-07-24

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 11

Registration Number: NCT05242445

Locations: 🇧🇪
SGS Belgium NV, Edegem, Belgium
🇪🇸
Hosp. Gral. Univ. Valencia, Valencia, Spain
🇵🇱
PUNKT ZDROWIA Hlebowicz Jakubowski Lekarze sp.p., Gdansk, Poland

and more 10 locations

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2

Active, not recruiting

Conditions: Colitis, Ulcerative

Interventions: Biological: JNJ-78934804
Drug: Placebo
Biological: Guselkumab
Biological: Golimumab

First Posted Date: 2022-02-16

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 577

Registration Number: NCT05242484

Locations: 🇯🇵
University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵
Gunma University Hospital, Maebashi, Japan

and more 396 locations

A Study of Ustekinumab Treatment in Children With Crohn's Disease

Completed

Conditions: Crohn's Disease

Interventions: Drug: Ustekinumab

First Posted Date: 2022-02-16

Last Posted Date: 2024-08-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 545

Registration Number: NCT05242458

Locations: 🇺🇸
ImproveCareNow, Inc.,, Burlington, Vermont, United States

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Seltorexant

First Posted Date: 2022-02-11

Last Posted Date: 2023-03-02

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10

Registration Number: NCT05236868

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: JNJ-77242113

First Posted Date: 2022-02-04

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 255

Registration Number: NCT05223868

Locations: 🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States
🇺🇸
Indiana Clinical Trial Center, Plainfield, Indiana, United States
🇺🇸
DermAssociates, PC, Rockville, Maryland, United States

and more 72 locations

Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Conditions: Warm Autoimmune Hemolytic Anemia

First Posted Date: 2022-02-03

Last Posted Date: 2024-12-20

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT05221619

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Phase 2

Terminated

Conditions: Dengue

Interventions: Drug: JNJ-64281802
Drug: Placebo

First Posted Date: 2022-01-21

Last Posted Date: 2024-12-10

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1256

Registration Number: NCT05201794

Locations: 🇧🇷
Centro Bangu - Centro Municipal de Saude Waldyr Franco, Rio de Janeiro, Brazil
🇧🇷
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base, Sao Jose do Rio Preto, Brazil
🇧🇷
Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte, Brazil

and more 35 locations

A Study of JNJ-64281802 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-64281802

First Posted Date: 2022-01-21

Last Posted Date: 2023-04-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 33

Registration Number: NCT05201937

Locations: 🇳🇱
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy